Literature DB >> 12549988

Drug treatment of orthostatic hypotension and vasovagal syncope.

William H Frishman1, Victor Azer, Domenic Sica.   

Abstract

Orthostatic hypotension is a common problem, estimated to occur in 5 out of every 1000 individuals and in as many as 7% to 17% of patients in an acute care setting. Moreover, orthostatic hypotension may be more prominent in elderly patients due to the increased intake of vasoactive medications and concomitant decrease in physiologic function, such as baroreceptor sensitivity, often seen with aging. Orthostatic hypotension is a fall in blood pressure on assuming an upright position. Absolute cutoffs for the drop in blood pressure are often difficult to determine because different patients exhibit varying degrees of tolerance to falls in blood pressure. Therefore, strict numerical criteria may lead to underdiagnosis and improper intervention. A thorough review of patient symptomatology combined with appropriate clinical tests should be employed to narrow the vast differential diagnosis and pinpoint the etiology. The fall in blood pressure seen in orthostatic hypotension results from the inability of the autonomic nervous system to adequately compensate for the 500 mL blood that is estimated to pool in the lower extremities on assuming an upright posture. The decrease in venous return results in a concomitant decrease in cardiac output and thus hypoperfusion of the cerebral circulation, possibly resulting in syncope or various other symptoms. A complete investigation should consider hypovolemia, removal of offending medications, primary autonomic disorders, secondary autonomic disorders and, of course, vasovagal syncope, the most common cause of syncope. Although further research is still necessary to rectify the disease process responsible for orthostatic hypotension, patients suffering from this disorder can effectively be treated through a combination of nonpharmacologic treatment, pharmacologic treatment and patient education. Agents such as fludrocortisone, midodrine and erythropoietin show promising results as therapeutic adjuncts. Treatment for recurrent vasovagal syncope includes increased salt intake, and various drug treatments, most of which are still under investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12549988     DOI: 10.1097/01.HDX.0000050416.53995.43

Source DB:  PubMed          Journal:  Heart Dis        ISSN: 1521-737X


  6 in total

Review 1.  Neurocardiogenic syncope.

Authors:  Carol Chen-Scarabelli; Tiziano M Scarabelli
Journal:  BMJ       Date:  2004-08-07

2.  Reduced iron stores and its effect on vasovagal syncope (simple faint).

Authors:  Julian M Stewart
Journal:  J Pediatr       Date:  2008-07       Impact factor: 4.406

3.  Dizziness in an older community dwelling population: a multifactorial syndrome.

Authors:  K G Gassmann; R Rupprecht
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

4.  Orthostatic heart rate does not predict symptomatic burden in pediatric patients with chronic orthostatic intolerance.

Authors:  Jeffrey R Boris; Jing Huang; Thomas Bernadzikowski
Journal:  Clin Auton Res       Date:  2019-08-05       Impact factor: 4.435

5.  5-HT is a potent relaxant in rat superior mesenteric veins.

Authors:  Stephanie W Watts; Emma S Darios; Bridget M Seitz; Janice M Thompson
Journal:  Pharmacol Res Perspect       Date:  2015-01-05

6.  Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in african americans.

Authors:  Thomas O Obisesan; Richard F Gillum; Stephanie Johnson; Nisser Umar; Deborah Williams; Vernon Bond; John Kwagyan
Journal:  Int J Alzheimers Dis       Date:  2012-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.